TDG-IN-1

Overview

TDG-IN-1 is an orally active, selective small-molecule inhibitor of thymine DNA glycosylase ( TDG ) with a K a of 1.46 nM. TDG-IN-1 impairs the DNA-binding ability of TDG, induces downregulated expression of DHX9 , accumulation of double-stranded RNA, and activation of the RIG-I/MDA5-MAVS pathway, while acting as a tumor suppressor, innate immune activator and immunostimulant. TDG-IN-1 inhibits the growth of p53-deficient tumor cells and xenograft tumors, and exerts a synthetic lethal effect with p53. TDG-IN-1 is applicable to the research of p53-deficient cancers.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > DNA Glycosylase | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-181440
• CAS No.: 3092641-80-7
• Molecular Formula: C13H14O4
• Molecular Weight: 234.25
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source